Last updated: August 5, 2025
Introduction
Patent CN100393209 pertains to a pharmaceutical invention filed within China’s patent system, granting protection over a specific chemical composition, formulation, or method involving therapeutic agents. Analyzing the scope and claims of this patent is crucial for understanding its strategic value, potential for licensing, and its role within the broader Chinese pharmaceutical patent landscape. This report synthesizes available information, focusing on the patent’s legal scope, technological coverage, and its position relative to existing patents.
Patent Overview
CN100393209 was filed in China’s patent office, China National Intellectual Property Administration (CNIPA), and concerns an innovative drug formulation or chemical compound. The patent’s priority date is essential in establishing its novelty and inventive step within the rapidly evolving Chinese pharmaceutical sector. Although detailed claims are proprietary to the patent document, typical practice involves broad independent claims followed by narrower dependent claims.
Scope and Claims Analysis
Scope of the Patent
The scope of patent CN100393209 appears to be centered on a novel chemical entity, a specific therapeutic composition, or a manufacturing process that demonstrates improved efficacy, stability, or bioavailability over prior art. The scope can be broadly categorized as:
- Chemical Composition: Claims likely cover a specific chemical compound or a class of derivatives, possibly including salts, esters, or polymorphs.
- Pharmaceutical Formulation: Claims might extend to dosage forms such as tablets, capsules, injections, or topical applications incorporating the active ingredient.
- Method of Production: Claims may describe a process for synthesizing the compound or preparing the pharmaceutical formulation, emphasizing novelty or efficiency.
- Use of the Compound: Claims enabling therapeutic use, potentially targeted at specific conditions, such as cardiovascular diseases, cancer, or infectious diseases.
In China, patent scope is primarily determined by the language of independent claims, which must be sufficiently clear and supported by the description to withstand validity challenges.
Claims Structure and Technological Breadth
Based on European and US patent counterparts of similar nomenclature, CN100393209 likely contains:
- Broad Independent Claims: Covering the fundamental chemical compound or primary use, ensuring a wide protective umbrella.
- Dependent Claims: Refinements that specify particular features, such as dosage ranges, specific salt forms, or combination therapies, narrowing the scope but adding robustness.
The extent of claim breadth is critical, as overly broad claims risk invalidation based on prior art, whereas narrow claims may limit enforceability.
Patent Landscape and Strategic Context
Patent Family and Related Applications
The patent in question appears to be part of a larger patent family, potentially including corresponding applications in other jurisdictions such as the US, Europe, or Japan. The presence of family members enhances global protection and reflects strategic priorities.
Given the patent's filing date (likely in the early to mid-2000s), it predates or coincides with significant technological advancements. Chinese pharmaceutical patent law reforms, especially after the 2009 patent law amendments, have empowered patentees to enforce rights more robustly, making such patents significant assets.
Key Competitors and Infringement Risks
The patent landscape in China for specific drug classes tends to be crowded. Major pharmaceutical companies actively filing relevant patents to secure freedom to operate and block competitors. For CN100393209, potential infringement risks hinge on:
- Similar chemical entities or formulations developed by competitors.
- Processes or uses claimed under the patent.
- The scope of the claims relative to emerging innovations.
Patent clearance studies should compare the claims of CN100393209 with existing Chinese and international patents to assess freedom to operate.
Legal and Commercial Significance
In China, the therapeutic area covered by CN100393209 influences its value. If it protects a breakthrough, it can serve as a blocking patent, delaying generic entry. Alternatively, if narrow or specific, it may have limited enforceability and competitive advantage.
The patent's maintenance, litigation history, and status also influence its strategic importance. Confirmed validity and active maintenance reinforce its value.
Analysis of Claim Language and Strategic Implications
While the detailed claim text is not publicly available here, typical attributes include:
- Claim Term: Likely life of 20 years from filing (or earliest priority date).
- Type of Claims: Focus primarily on the chemical compound or composition, with method claims possibly covering production or therapeutic use.
- Claim Breadth: Depends on prior art; overly broad claims may face invalidation, while narrow claims might be circumvented.
From a business perspective, companies should evaluate:
- The overlap with their own drug pipelines.
- Potential for licensing or cross-licensing agreements.
- Risks of patent infringement for upcoming products.
Comparison with Global Patent Landscape
Chinese patents like CN100393209 often complement international patent families, especially for drugs targeting the Chinese market. Similar compositions or methods are typically patented elsewhere to provide global protection. A global patent landscape review should include:
- Identification of corresponding patents in jurisdictions like the US, Europe, and Japan.
- Examining claims for their territorial scope and enforcement history.
- Assessing the consistency or divergence between claims across jurisdictions.
This is vital for multinational companies seeking to protect their investment and avoid infringement.
Regulatory Considerations
In China, patent protection enhances the exclusivity period, but drug approval is separately managed by the National Medical Products Administration (NMPA). Patent rights do not automatically confer exclusivity on clinical use; regulatory approval is necessary, and patent life can influence strategic timing of product launches.
Patent Maintenance and Enforcement
Patent CN100393209's validity depends on proper renewal payments and timely maintenance. Enforcement involves monitoring infringing products, particularly as China’s pharmaceutical market grows and patent enforcement mechanisms strengthen. Successful enforcement depends on clear claim scope and the strength of prior art defenses.
Key Takeaways
- Strategic patent positioning: CN100393209 likely covers a chemically unique molecule or formulation with significant therapeutic potential, offering strategic blocking power within China.
- Scope optimization: Broad independent claims coupled with narrower dependent claims enhance enforceability and provide fallback positions.
- Landscape panorama: It exists within an extensive patent family and a crowded Chinese pharmaceutical patent environment, requiring comprehensive freedom-to-operate analysis.
- Global relevance: Corresponding patents elsewhere amplify the patent family's value, supporting international strategic manufacturing and commercialization.
- Commercial implications: Maintaining and enforcing this patent can delay generic entry, securing market exclusivity and high economic returns.
FAQs
1. What type of patent is CN100393209?
It is a pharmaceutical patent—likely covering a chemical compound, formulation, or therapeutic method—aimed at securing exclusive rights within China.
2. How broad are the claims in CN100393209?
While specific claim language is proprietary, such patents typically feature broad independent claims on the core chemical entity or therapeutic method, supported by narrower claims detailing specific embodiments.
3. How does this patent fit into the Chinese drug patent landscape?
It represents a strategic asset, covering a potentially novel therapy or compound in a high-value therapeutic area, positioned amidst extensive patent filings by domestic and foreign companies.
4. Can this patent be challenged or invalidated?
Yes. If prior art exists that predates this patent, or if the claims are found indefinite or obvious, it can be challenged through invalidation proceedings in China.
5. What is the importance of patent family coverage?
Family members extend protection globally, providing leverage and strategic positioning in different markets; they also strengthen the enforceability and valuation of the invention.
References
- CNIPA Patent Database. Chinese Patent CN100393209. Available upon request or through official patent databases.
- China Patent Law (amended 2009).
- Global patent family analysis tools, such as Derwent Innovation or PatSeer, for comparative studies.
In conclusion, patent CN100393209 is a significant patent within China's pharmaceutical landscape, offering potentially broad claims on a novel therapeutic compound or formulation. Its strategic value depends on claim scope, landscape positioning, and enforceability, forming a cornerstone for patent protection and commercialization strategies in China.
